An observational study into the usage and efficacy of Crestor [rosuvastatin] 5mg as a start dosage in achieving the LDL-C [low-density lipoprotein cholesterol] target level in both statin-naive and treated primary and secondary prevention patients with a high risk of a cardiovascular event.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 29 Aug 2011
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms OPTIMAL
- Sponsors AstraZeneca
- 07 Feb 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
- 26 Nov 2006 New trial record.